STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment
STAT News · LC · trust 43/100
Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year.
Read the original at STAT News →
Open in TruthVane →